Kennard Alice, Glasgow Nicholas, Rainsford Suzanne, Talaulikar Girish
Department of Renal Medicine, Canberra Health Services, Canberra, Australian Capital Territory, Australia.
School of Medicine, Australian National University, Canberra, Australian Capital Territory, Australia.
Intern Med J. 2023 Apr;53(4):465-472. doi: 10.1111/imj.15759. Epub 2022 May 30.
Frailty is a multidimensional clinical syndrome characterised by low physical activity, reduced strength, accumulation of multi-organ deficits, decreased physiological reserve and vulnerability to stressors. Frailty pathogenesis and 'inflammageing' is augmented by uraemia, leading to a high prevalence of frailty potentially contributing to adverse outcomes in patients with advanced chronic kidney disease (CKD), including end-stage kidney disease (ESKD). The presence of frailty is a stronger predictor of CKD outcomes than estimated glomerular filtration rate and more aligned with dialysis outcomes than age. Frailty assessment should form part of routine assessment of patients with CKD and inform key medical transitions. Frailty screening and interventions in CKD/ESKD should be a research priority.
衰弱是一种多维度的临床综合征,其特征为身体活动量低、力量下降、多器官功能缺陷累积、生理储备减少以及对应激源的易损性。尿毒症会加剧衰弱的发病机制和“炎症衰老”,导致衰弱的高患病率,这可能会导致晚期慢性肾脏病(CKD)患者出现不良后果,包括终末期肾病(ESKD)。衰弱的存在比估计的肾小球滤过率更能预测CKD的预后,并且比年龄更能反映透析结果。衰弱评估应成为CKD患者常规评估的一部分,并为关键的医疗转变提供依据。CKD/ESKD患者的衰弱筛查和干预应成为研究重点。